Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

41. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study Full Text available with Trip Pro

Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) /dom.14263. Online ahead of print. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study , , , , , , , , , Affiliations Expand Affiliations 1 Department of Hepatology, Nanpuh Hospital, Kagoshima, Japan. 2 Department of Internal Medicine, Kagoshima Kouseiren Hospital, Kagoshima, Japan. 3 Jiaikai Clinic, Kagoshima, Japan. 4 Uenomachi-Kajiya Clinic, Kagoshima, Japan. 5 Tempozan Naika Medical Clinic, Kagoshima, Japan

2021 EvidenceUpdates

42. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Actions . 2020 Dec 22;ehaa943. doi: 10.1093/eurheartj/ehaa943. Online ahead of print. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiovascular Medicine, The Ohio State University, 473 West 12th Ave., Columbus, OH 43210,USA. 2 Vanderbilt University Medical Center, 1211 Medical Center

2021 EvidenceUpdates

43. Handout on type 2 diabetes in youth for medical students or residents

Handout on type 2 diabetes in youth for medical students or residents application/vnd.openxmlformats-officedocument.wordprocessingml.document

2021 Pediatric Endocrine Society

44. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial Full Text available with Trip Pro

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial - PubMed This site needs JavaScript to work (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Feb;23(2):569-580. doi: 10.1111/dom.14254. Epub 2020 Dec 6. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division

2021 EvidenceUpdates

45. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Med Actions . 2021 Jan;38(1):e14411. doi: 10.1111/dme.14411. Epub 2020 Oct 9. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials , , , , , Affiliations Expand Affiliation 1 Department of Endocrinology, Affiliated Hospital of Medical College Qingdao University, Qingdao, China. PMID: 33000477 DOI: Item in Clipboard Review Efficacy and safety of endothelin receptor antagonists in type 2

2021 EvidenceUpdates

46. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial Full Text available with Trip Pro

Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial - PubMed This site needs JavaScript to work (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Feb;23(2):609-618. doi: 10.1111/dom.14259. Epub 2020 Dec 13. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial , , , , Affiliations Expand Affiliations 1 Division

2021 EvidenceUpdates

47. Benefits of CPAP on glycemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnea: a meta-analysis

Benefits of CPAP on glycemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnea: a meta-analysis Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) . 2021 Feb;23(2):540-548. doi: 10.1111/dom.14247. Epub 2020 Dec 2. Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis , , , Affiliations Expand Affiliations 1 Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, China. 2 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Medical College, Xi'an

2021 EvidenceUpdates

48. Sitagliptin for the Prevention and Treatment of Perioperative Hyperglycaemia in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Randomised Controlled Trial Full Text available with Trip Pro

Sitagliptin for the Prevention and Treatment of Perioperative Hyperglycaemia in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Randomised Controlled Trial Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) navigation Diabetes Obes Metab Actions . 2021 Feb;23(2):480-488. doi: 10.1111/dom.14241. Epub 2020 Dec 2. Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Emory University, Atlanta, Georgia. 2 Joseph B. Whitehead Department of Surgery, Emory University, Atlanta, Georgia. 3 Rollins School of Public

2021 EvidenceUpdates

49. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies Full Text available with Trip Pro

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Metab Actions . 2021 Feb;23(2):549-560. doi: 10.1111/dom.14248. Epub 2020 Nov 24. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3 Clinical

2021 EvidenceUpdates

50. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study

The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Permalink Copy Page navigation Eur Heart J Actions . 2020 Nov 19;ehaa956. doi: 10.1093/eurheartj/ehaa956. Online ahead of print. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study , , Affiliations Expand Affiliations 1 Melbourne EpiCentre, University of Melbourne, The Royal Melbourne Hospital - City Campus, 7 East, Main Building, Grattan Street, Parkville Victoria 3050

2021 EvidenceUpdates

51. Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis Full Text available with Trip Pro

Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) /journal.pmed.1003434. eCollection 2020 Nov. Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis , , , , , , , , Affiliations Expand Affiliations 1 Center for Research in Indigenous Health, Wuqu' Kawoq, Tecpán, Guatemala. 2 Division of Hospital Medicine, Department of Internal Medicine, National Clinician Scholars Program, University of Michigan, Ann Arbor, Michigan, United States of America. 3 Medicine-Pediatrics Residency

2021 EvidenceUpdates

52. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Department of Internal Medicine, University

2020 EvidenceUpdates

53. Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S.

Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S. Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) . 2020 Nov 11;dc202045. doi: 10.2337/dc20-2045. Online ahead of print. Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S , , , , , , Affiliations Expand Affiliations 1 Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia. 2 Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K. 3 Leicester NIHR Biomedical

2020 EvidenceUpdates

54. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review

Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Actions . 2020 Nov 7;e13817. doi: 10.1111/ijcp.13817. Online ahead of print. Impact of Ramadan-focused diabetes education on hypoglycemia risk and metabolic control for patients with type 2 diabetes mellitus: A systematic review , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Chronic Diseases Center, Family and Community Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 2 Department of Data Science, King Hussein Faculty for Computer Sciences, Princess

2020 EvidenceUpdates

55. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes Full Text available with Trip Pro

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Metab Actions . 2020 Oct 20. doi: 10.1111/dom.14234. Online ahead of print. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes , , , , , , , Affiliations Expand Affiliations 1 Yale University School of Medicine, New Haven, Connecticut, USA. 2 Diabetes Research Centre, University of Leicester, Leicester, UK. 3 Boehringer Ingelheim International GmbH, Ingelheim, Germany. 4 Boehringer Ingelheim

2020 EvidenceUpdates

56. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE Full Text available with Trip Pro

Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. 2 Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3 HCA Midwest Health Heart and Vascular Institute, Overland Park, Kansas, USA. 4 Scripps Whittier Diabetes Institute, San Diego

2020 EvidenceUpdates

57. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study

Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Nov 9;dc200358. doi: 10.2337/dc20-0358. Online ahead of print. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Centers for Disease Control and Prevention, Atlanta

2020 EvidenceUpdates

58. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) navigation Diabetes Care Actions . 2020 Dec;43(12):3024-3033. doi: 10.2337/dc20-1447. Epub 2020 Oct 14. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial , , , , , , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators Australian JDRF Closed-Loop Research Group : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1

2020 EvidenceUpdates

59. Incident Type 2 Diabetes and Risk of Fracture: A Comparative Cohort Analysis Using U.K. Primary Care Records Full Text available with Trip Pro

Incident Type 2 Diabetes and Risk of Fracture: A Comparative Cohort Analysis Using U.K. Primary Care Records Incident Type 2 Diabetes and Risk of Fracture: A Comparative Cohort Analysis Using U.K. Primary Care Records - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) : Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Nov 4;dc201220. doi: 10.2337/dc20-1220. Online ahead of print. Incident Type 2 Diabetes

2020 EvidenceUpdates

60. Oral semaglutide (Rybelsus) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

Oral semaglutide (Rybelsus) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus | Report | National Health Care Institute You are here: Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus Search within English part of National Health Care Institute Search Oral semaglutide (Rybelsus® (...) ) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus Zorginstituut Nederland has completed its assessment, using the parallel procedure CBG-ZIN, whether oral semaglutide (Rybelsus®) is interchangeable with a product that is included in the medication reimbursement system (GVS). The Zorginstituut's advice is to include oral semaglutide (Rybelsus®) in Appendix 1B and Appendix 2 of the Health Insurance Regulation and to impose additional conditions. Registered indication Semaglutide

2020 National Health Care Institute (Zorginstituut Nederland)